CRISPR Therapeutics (BOVESPA:C2RS34) - Stock Price, News & Analysis

C2RS34 Stock Overview

C2RS34 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 37.62% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

CRISPR Therapeutics AG Competitors

Blau Farmacêutica

BOVESPA:BLAU3

R$1.8b

Biomm

BOVESPA:BIOM3

R$1.5b

Hypera

BOVESPA:HYPE3

R$18.4b

Blueprint Medicines

NasdaqGS:BPMC

US$5.5b

Price History & Performance

Summary of all time highs, changes and price drops for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$35.73
52 Week High	US$55.26
52 Week Low	US$25.00
Beta	1.74
1 Month Change	-20.78%
3 Month Change	-10.59%
1 Year Change	14.63%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-14.96%

Recent updates

Shareholder Returns

	C2RS34	BR Biotechs	BR Market
7D	-9.7%	-3.0%	-1.0%
1Y	14.6%	-9.0%	13.1%

Return vs Industry: C2RS34 exceeded the BR Biotechs industry which returned -9% over the past year.

Return vs Market: C2RS34 exceeded the BR Market which returned 13.1% over the past year.

Price Volatility

Is C2RS34's price volatile compared to industry and market?
C2RS34 volatility
C2RS34 Average Weekly Movement	12.6%
Biotechs Industry Average Movement	9.4%
Market Average Movement	4.6%
10% most volatile stocks in BR Market	8.7%
10% least volatile stocks in BR Market	2.2%

Stable Share Price: C2RS34's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine C2RS34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	407	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
C2RS34 fundamental statistics
Market cap	R$24.24b
Earnings (TTM)	-R$787.96m
Revenue (TTM)	R$1.90b

12.7x

P/S Ratio

-30.8x

P/E Ratio

Is C2RS34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C2RS34 income statement (TTM)
Revenue	US$371.21m
Cost of Revenue	US$517.58m
Gross Profit	-US$146.38m
Other Expenses	US$7.23m
Earnings	-US$153.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.81
Gross Margin	-39.43%
Net Profit Margin	-41.38%
Debt/Equity Ratio	0%

How did C2RS34 perform over the long term?

See historical performance and comparison

C2RS34 Stock Overview

Rewards

Risk Analysis

CRISPR Therapeutics AG Competitors

BOVESPA:BLAU3

R$1.8b

BOVESPA:BIOM3

R$1.5b

BOVESPA:HYPE3

R$18.4b

NasdaqGS:BPMC

US$5.5b

Price History & Performance

Recent News & Updates

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

Recent updates

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Shareholder Returns

Price Volatility

About the Company

CRISPR Therapeutics AG Fundamentals Summary

12.7x

-30.8x

Earnings & Revenue